Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)
Status:
Terminated
Trial end date:
2011-03-04
Target enrollment:
Participant gender:
Summary
This study will evaluate the hepatic (liver) and plasma pharmacokinetics of Vaniprevir
(MK-7009) by evaluation of ribonucleic acid (RNA) of the hepatitis C virus (HCV) in genotype
1, HCV-infected participants.